Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ascletis PharmaASCLF -1.54%38 Price-to-Tangible-Book is 4.62 as of Sep. 01, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,129 Biotechnology companies, Ascletis Pharma ranks worse than 60.32% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
Ascletis Pharma Price-to-Tangible-Book Related Terms
Ascletis Pharma Price-to-Tangible-Book Historical Data
* Premium members only.
The historical data trend for Ascletis Pharma's Price-to-Tangible-Book can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASCLF vs VRTX, REGN, MRNA: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, Ascletis Pharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
Ascletis Pharma (ASCLF) has a Price-to-Tangible-Book of 4.62 as of Sep. 01, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ascletis Pharma and its competitors. According to the industry distribution chart, Ascletis Pharma ranks #681 out of 1129 companies in the Biotechnology industry, placing it in the top 60.3%.
Is Ascletis Pharma's Price-to-Tangible-Book too high?
Ascletis Pharma's current Price-to-Tangible-Book is 4.62. The Biotechnology industry median Price-to-Tangible-Book is 3.25. Ascletis Pharma's value of 4.62 is 42.2% above this industry median. Based on the distribution chart, Ascletis Pharma ranks #681 out of 1129 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's Price-to-Tangible-Book compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #681 out of 1129 companies for Price-to-Tangible-Book. This places Ascletis Pharma in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.25. Ascletis Pharma's value of 4.62 is 42.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.25, based on 1,129 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascletis Pharma's current Price-to-Tangible-Book of 4.62 is 42.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on Ascletis Pharma and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascletis Pharma's current Price-to-Tangible-Book is 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.28 — trading 6300% above its estimated fair value. The current Price-to-Tangible-Book is 4.62 and 42.2% above the Biotechnology industry median of 3.25. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current Price-to-Tangible-Book is 4.62 as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.28 is trading 6300% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
Price-to-Tangible-Book: 4.62
GF Value™: $0.02 vs. price of $1.28 (6300% above fair value)
Industry Position: 42.2% above the Biotechnology median (#681 of 1129)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 
